Multiple Endocrine Neoplasia: A Genetically Diverse Group of Familial Tumor Syndromes

Abstract

Multiple endocrine neoplasia (MEN) syndrome is a familial cancer syndrome characterized by neuroendocrine tumors. The syndrome encompasses four major subtypes: MEN1, MEN2A, MEN2B, and MEN4. MEN1 is caused by mutations in the MEN1 gene, MEN2A and MEN2B are caused by mutations in RET, and MEN4 is caused by mutations in CDKNB1. All are inherited in an autosomal dominant pattern, but de novo cases do arise. While all subtypes are associated with neuroendocrine tumors, each has characteristic organ involvement. Identifying patients with the syndrome can aid in proper screening and treatment.

Keywords

multiple endocrine neoplasia - MEN1 - MEN2 - MEN4 - neuroendocrine tumors - familial cancer syndrome

• References

• 1 Chandrasekharappa SC, Guru SC, Manickam P , et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276 (5311) 404-407
• 2 Brandi ML, Gagel RF, Angeli A , et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86 (12) 5658-5671
• 3 Simonds WF, James-Newton LA, Agarwal SK , et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 2002; 81 (1) 1-26
• 4 Bergman L, Teh B, Cardinal J , et al. Identification of MEN1 gene mutations in families with MEN 1 and related disorders. Br J Cancer 2000; 83 (8) 1009-1014
• 5 Hannan FM, Nesbit MA, Christie PT , et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab 2008; 4 (1) 53-58
• 6 Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29 (1) 22-32
• 7 Stålberg P, Grimfjärd P, Santesson M , et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab 2004; 89 (5) 2326-2337
• 8 Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003; 113 (7) 881-889
• 9 Schnepp RW, Mao H, Sykes SM , et al. Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 2004; 279 (11) 10685-10691
• 10 Thakker RV, Newey PJ, Walls GV , et al; Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97 (9) 2990-3011
• 11 Goudet P, Dalac A, Le Bras M , et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines. J Clin Endocrinol Metab 2015; 100 (4) 1568-1577
• 12 Newey PJ, Thakker RV. Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr Pract 2011; 17 (Suppl. 03) 8-17
• 13 Doherty GM, Lairmore TC, DeBenedetti MK. Multiple endocrine neoplasia type 1 parathyroid adenoma development over time. World J Surg 2004; 28 (11) 1139-1142
• 14 Lairmore TC, Govednik CM, Quinn CE, Sigmond BR, Lee CY, Jupiter DC. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 2014; 156 (6) 1326-1334 , discussion 1334–1335
• 15 Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. Am J Surg 2006; 191 (3) 418-423
• 16 Goudet P, Murat A, Binquet C , et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34 (2) 249-255
• 17 Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013; 92 (3) 135-181
• 18 Baloch Z, Livolsi V. Pathology of thyroid and parathyroid disease. In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010: 493-544
• 19 Pritchard DM. Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1. Gut 2007; 56 (5) 606-607
• 20 Anlauf M, Enosawa T, Henopp T , et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol 2008; 32 (7) 1101-1105
• 21 Pipeleers-Marichal M, Somers G, Willems G , et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322 (11) 723-727
• 22 Anlauf M, Perren A, Henopp T , et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut 2007; 56 (5) 637-644
• 23 Thevenon J, Bourredjem A, Faivre L , et al. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study. Hum Mol Genet 2013; 22 (10) 1940-1948
• 24 Bartsch DK, Slater EP, Albers M , et al. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab 2014; 99 (11) E2387-E2391
• 25 Newey PJ, Jeyabalan J, Walls GV , et al. Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2009; 94 (10) 3640-3646
• 26 Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol 2014; 25 (1) 65-79
• 27 Klimstra DS, Arnold R, Capella C , et al. Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carniero F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010: 322-326
• 28 Trouillas J, Labat-Moleur F, Sturm N , et al; Groupe d'études des Tumeurs Endocrines. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008; 32 (4) 534-543
• 29 Scheithauer B. The pituitary and sellar region. In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010: 460-492
• 30 Wells Jr SA, Asa SL, Dralle H , et al; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25 (6) 567-610
• 31 Mathew CG, Chin KS, Easton DF , et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987; 328 (6130) 527-528
• 32 Simpson NE, Kidd KK, Goodfellow PJ , et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987; 328 (6130) 528-530
• 33 Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42 (2) 581-588
• 34 Santoro M, Rosati R, Grieco M , et al. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990; 5 (10) 1595-1598
• 35 Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 2014; 120 (13) 1920-1931
• 36 Eng C, Mulligan LM, Smith DP , et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995; 43 (1) 123-127
• 37 Elisei R, Romei C, Cosci B , et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92 (12) 4725-4729
• 38 Brauckhoff M, Machens A, Hess S , et al. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 2008; 144 (6) 1044-1050 , discussion 1050–1053
• 39 Giri D, McKay V, Weber A, Blair JC. Multiple endocrine neoplasia syndromes 1 and 2: manifestations and management in childhood and adolescence. Arch Dis Child 2015; 100 (10) 994-999
• 40 Albores-Saavedra JA, Krueger JE. C-cell hyperplasia and medullary thyroid microcarcinoma. Endocr Pathol 2001; 12 (4) 365-377
• 41 Guyétant S, Josselin N, Savagner F, Rohmer V, Michalak S, Saint-André JP. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Mod Pathol 2003; 16 (8) 756-763
• 42 Kaserer K, Scheuba C, Neuhold N , et al. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 2001; 25 (10) 1245-1251
• 43 Etit D, Faquin WC, Gaz R, Randolph G, DeLellis RA, Pilch BZ. Histopathologic and clinical features of medullary microcarcinoma and C-cell hyperplasia in prophylactic thyroidectomies for medullary carcinoma: a study of 42 cases. Arch Pathol Lab Med 2008; 132 (11) 1767-1773
• 44 Heizmann O, Haecker FM, Zumsteg U, Müller B, Oberholzer M, Oertli D. Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a. Eur J Surg Oncol 2006; 32 (1) 98-102
• 45 Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 1996; 77 (4) 750-756
• 46 Matias-Guiu X, DeLellis RA, Moley JF , et al. Medullary thyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. WHO Health Organization Classification of Tumours: Pathology and Genetics Tumours of Endocrine Organs. Lyons: IARC; 2004: 86-91
• 47 Lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma syndromes: genetics and management update. Curr Oncol 2014; 21 (1) e8-e17
• 48 Pomares FJ, Cañas R, Rodriguez JM, Hernandez AM, Parrilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf) 1998; 48 (2) 195-200
• 49 DeLellis R, Mangray S. The adrenal glands. In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010: 545-586
• 50 Lloyd RV. Adrenal cortical tumors, pheochromocytomas and paragangliomas. Mod Pathol 2011; 24 (Suppl. 02) S58-S65
• 51 Korpershoek E, Petri BJ, Post E , et al. Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome. Neoplasia 2014; 16 (10) 868-873
• 52 Coyle D, Friedmacher F, Puri P. The association between Hirschsprung's disease and multiple endocrine neoplasia type 2a: a systematic review. Pediatr Surg Int 2014; 30 (8) 751-756
• 53 Cohen MS, Phay JE, Albinson C , et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 2002; 235 (5) 648-654 , discussion 654–655
• 54 Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol 2009; 161 (6) 1217-1224
• 55 Rothberg AE, Raymond VM, Gruber SB, Sisson J. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid 2009; 19 (6) 651-655
• 56 Verga U, Fugazzola L, Cambiaghi S , et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 2003; 59 (2) 156-161
• 57 Fenoglio-Preiser C, Nofsinger A, Stemmerman G, Lantz P, Isaacson P. Gastrointestinal Pathology: An Atlas and Text. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008
• 58 Yin M, King SK, Hutson JM, Chow CW. Multiple endocrine neoplasia type 2B diagnosed on suction rectal biopsy in infancy: a report of 2 cases. Pediatr Dev Pathol 2006; 9 (1) 56-60
• 59 Fritz A, Walch A, Piotrowska K , et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 2002; 62 (11) 3048-3051
• 60 Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009; 94 (5) 1826-1834
• 61 Tsukada T, Nagamura Y, Ohkura N. MEN1 gene and its mutations: basic and clinical implications. Cancer Sci 2009; 100 (2) 209-215
• 62 Pellegata NS, Quintanilla-Martinez L, Siggelkow H , et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006; 103 (42) 15558-15563
• 63 Georgitsi M. MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. Best Pract Res Clin Endocrinol Metab 2010; 24 (3) 425-437
• 64 Georgitsi M, Raitila A, Karhu A , et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007; 92 (8) 3321-3325
• 65 Ozawa A, Agarwal SK, Mateo CM , et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007; 92 (5) 1948-1951
• 66 Molatore S, Marinoni I, Lee M , et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 2010; 31 (11) E1825-E1835
• 67 Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab 2011; 96 (4) E701-E706
• 68 Tonelli F, Giudici F, Giusti F , et al. A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome. Eur J Endocrinol 2014; 171 (2) K7-K17
• 69 Malanga D, De Gisi S, Riccardi M , et al. Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur J Endocrinol 2012; 166 (3) 551-560
• 70 Occhi G, Regazzo D, Trivellin G , et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 2013; 9 (3) e1003350